https://scholars.lib.ntu.edu.tw/handle/123456789/566337
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Bornstein J. | en_US |
dc.contributor.author | Roux S. | en_US |
dc.contributor.author | Petersen L.K. | en_US |
dc.contributor.author | LI-MIN HUANG | en_US |
dc.contributor.author | Dobson S.R. | en_US |
dc.contributor.author | Pitisuttithum P. | en_US |
dc.contributor.author | Diez-Domingo J. | en_US |
dc.contributor.author | Schilling A. | en_US |
dc.contributor.author | Ariffin H. | en_US |
dc.contributor.author | Tytus R. | en_US |
dc.contributor.author | Rupp R. | en_US |
dc.contributor.author | Senders S. | en_US |
dc.contributor.author | Engel E. | en_US |
dc.contributor.author | Ferris D. | en_US |
dc.contributor.author | Kim Y.-J. | en_US |
dc.contributor.author | Kim Y.T. | en_US |
dc.contributor.author | Kurugol Z. | en_US |
dc.contributor.author | Bautista O. | en_US |
dc.contributor.author | Nolan K.M. | en_US |
dc.contributor.author | Sankaranarayanan S. | en_US |
dc.contributor.author | Saah A. | en_US |
dc.contributor.author | Luxembourg A. | en_US |
dc.date.accessioned | 2021-06-24T07:15:57Z | - |
dc.date.available | 2021-06-24T07:15:57Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 0031-4005 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099326316&doi=10.1542%2fPEDS.2019-4035&partnerID=40&md5=dba5f64b309829cb9af5681f5cc496d4 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/566337 | - |
dc.description.abstract | BACKGROUND AND OBJECTIVES: Human papillomavirus (HPV) antibody responses to the 9-valent human papillomavirus (9vHPV) vaccine among girls and boys (aged 9-14 years) receiving 2-dose regimens (months 0, 6 or 0, 12) were noninferior to a 3-dose regimen (months 0, 2, 6) in young women (aged 16-26 years) 4 weeks after last vaccination in an international, randomized, open-label trial (NCT01984697). We assessed response durability through month 36. METHODS: Girls received 2 (months 0 and 6 [0, 6]: n = 301; months 0 and 12 [0, 12]: n = 151) or 3 doses (months 0,2, and 6 [0, 2, 6]: n = 301); boys received 2 doses ([0, 6]: n = 301; [0, 12]: n = 150); and young women received 3 doses ([0, 2, 6]: n = 314) of 9vHPV vaccine. Anti-HPV geometric mean titers (GMTs) were assessed by competitive Luminex immunoassay (cLIA) and immunoglobulin G-Luminex immunoassay (IgG-LIA) through month 36. RESULTS: Anti-HPV GMTs were highest 1 month after the last 9vHPV vaccine regimen dose, decreased sharply during the subsequent 12 months, and then decreased more slowly. GMTs 2 to 2.5 years after the last regimen dose in girls and boys given 2 doses were generally similar to or greater than GMTs in young women given 3 doses. Across HPV types, most boys and girls who received 2 doses (cLIA: 81%-100%; IgG-LIA: 91%-100%) and young women who received 3 doses (cLIA: 78%-98%; IgG-LIA: 91%-100%) remained seropositive 2 to 2.5 years after the last regimen dose. CONCLUSIONS: Antibody responses persisted through 2 to 2.5 years after the last dose of a 2-dose 9vHPV vaccine regimen in girls and boys. In girls and boys, antibody responses generated by 2 doses administered 6 to 12 months apart may be sufficient to induce high-level protective efficacy through at least 2 years after the second dose. Copyright ? 2021 by the American Academy of Pediatrics | - |
dc.publisher | American Academy of Pediatrics | - |
dc.relation.ispartof | Pediatrics | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | Wart virus vaccine; biological marker; virus antibody; Wart virus vaccine; abdominal pain; adolescent; adult; age distribution; allergic encephalitis; antibody response; antibody titer; Article; chemiluminescence immunoassay; child; cohort analysis; controlled study; dosage schedule comparison; drug dose regimen; drug response; drug withdrawal; epileptic state; female; follow up; geometry; heart arrest; human; human experiment; immunoassay; immunogenicity; immunoglobulin G luminex immunoassay; male; multicenter study; open study; priority journal; randomized controlled trial; school child; sex difference; single drug dose; transient urticaria; urticaria; verruca vulgaris; Alphapapillomavirus; blood; dose response; follow up; immunology; young adult; Adolescent; Adult; Alphapapillomavirus; Antibodies, Viral; Biomarkers; Child; Dose-Response Relationship, Immunologic; Female; Follow-Up Studies; Humans; Male; Papillomavirus Vaccines; Young Adult | - |
dc.title | Three-year follow-up of 2-dose versus 3-dose HPV vaccine | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1542/PEDS.2019-4035 | - |
dc.identifier.pmid | 33386332 | - |
dc.identifier.scopus | 2-s2.0-85099326316 | - |
dc.relation.pages | e20194035 | - |
dc.relation.journalvolume | 147 | - |
dc.relation.journalissue | 1 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Epidemiology and Preventive Medicine | - |
crisitem.author.dept | National Taiwan University Children's Hospital | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.orcid | 0000-0002-9291-260X | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Public Health | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。